Avid Bioservices Inc (CDMO)

[biopharm]

Nice conference call as they are trying so nicely, as legal as possible, to hide the IP assets that will dwarf CDMO profits that are not based upon IP of PS Targeting. Flipped PS begins 20 years earlier for Alzheimer's etc before any signs are picked up by your MD

That is a lot of CDMO business as the time is nearing.

_______

Role of Tumor Necrosis Factor in Neurodegeneration

published May 28, 2019

...
...
...

Apoptosis and necroptosis: Apoptosis is a form of programmed cell death mediated by caspases. Morphological features of apoptosis include expulsion of phosphatidylserine (PtdSer) to the outer side of the plasma membrane, chromatin condensation and DNA cleavage. Exposure of PtdSer to surface signals macrophages and other phagocytic cells to clear the debris.

In contrast Necroptosis is a form of Ne- crosis where plasma membrane permeability increases and organelle swells, this process is not mediated by caspases. Both apoptosis and necroptosis are reported during activation of TNF-a mediated pathway in the CNS [8].
...
...
Alzheimer’s Diseases (AD), Parkinson’s Disease (PD), Multiple Sclerosis (MS), Cerebral Ischemia (CI) and Amyotrophic Lateral Scle- rosis (ALS), traumatic brain injury (TBI), epilepsy are some of the major Neurodegenerative diseases where TNF- a is directly involved. Apart from these major diseases some other less common diseases like Creutzfeldt-Jakob’s disease (CJD), Huntington’s disease (HD), lysosomal storage diseases (LSDs), are also seen in individuals where TNF-a act as a prime factor in progression of that particular disease. We are discussing involvement of TNF-a and its receptors only in few major neurodegenerative diseases.
...
...

https://www.ecronicon.com/ecemr/pdf/ECEMR-04-00098.pdf

_____

After Dr. Wolchok's finding and publication/presentations on the subject, PPHM PdtSer-Targeting is the perfect replacement for OX40 and alikes in CAR-T for all solid cancers. ex-CEO King said renewed interest and Dr/ Wolchok said a test on humans is designed and waits for the company (understand->'the green light') to start.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137369922

_____

It was nice to hear the new CEO say one of the reasons Avid is so successful is due to its past history. Steve King was part of all that and even SK knew Alzheimer's etc would be treated ...required to be treated with PS Targeting

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=123918105

____

One has to ask themselves why there was no mention on the conference call regarding IP assets that will have quantum leap rise levels of knowledge and maybe Roger Lias was booted off as CEO due to him saying PS Targeting had residual value ?

Maybe now the BODs were told by legal they should not answer the IP asset valuation questions and analysts were forewarned ?

Maybe now, investors will like the CDMO valuation being staged, as the IP is being controlled in the background. Think about it...no longer would DOZENS of "key" FDA approved drugs be required with the introduction of PS Targeting.

Paradigm shifts scare the hell out of the Big Pharma aristocrats ( nice way of saying Mafia ) ... but knowledge continues to build and many a PhD will shake the tree that has fed Big Pharma for a hundred years and new seeds will be planted.

For residual value as Roger Lias said and voiced by Ronin Capital John Springs Stafford, why in the world would someone stealthily build / create a start up 30 days prior and come out of the blue to play let's make a deal with the IP assets ...as Oncologie Inc "backers" did.

Avid Bioservices NEVER mentioned or gave guidance to how much revenue comes now or future ...based upon the IP assets in the hands of Oncologie or UTSWM etc

____________

Of course some don't want to mention how the next Alzheimer's drug would be critical with PS Targeting and with Alzheimer's protein pathway changes about 20 years in advance, that is astronomical amount taking PS Targeting for treatment

___________

Good luck Eli Lilly and what is Steve Demattos brothers name again...oh yes, Ronald DeMattos! : )

Say hello to Cheryl Leyns at Merck ( Dr David Holtzman her advisor etc) as she knows Alzheimer's requires PS Targeting. Imagine that...some hedge funds spend hours trying to figure some of this out.

____________

- no 12 different drugs needed in I-O combination
...
...
PS both play roles in many biological processes, such as fibril formation in neurodegenerative diseases and wound healing.21,22
...
...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138657855